Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Amortizatization of Intangibles (2023 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Amortizatization of Intangibles data on record, last reported at $82000.0 in Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles rose 6.49% year-over-year to $82000.0; the TTM value through Sep 2025 reached $321000.0, up 6.64%, while the annual FY2024 figure was $306000.0, 6.25% up from the prior year.
  • Amortizatization of Intangibles reached $82000.0 in Q3 2025 per BTAI's latest filing, up from $81000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $82000.0 in Q3 2025 and bottomed at $70000.0 in Q1 2023.
  • Average Amortizatization of Intangibles over 3 years is $76000.0, with a median of $75000.0 recorded in 2024.
  • Peak YoY movement for Amortizatization of Intangibles: grew 4.17% in 2024, then grew 8.0% in 2025.
  • A 3-year view of Amortizatization of Intangibles shows it stood at $74000.0 in 2023, then rose by 6.76% to $79000.0 in 2024, then rose by 3.8% to $82000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $82000.0 in Q3 2025, $81000.0 in Q2 2025, and $79000.0 in Q1 2025.